View full meeting coverage »

Eyetube Meeting Coverage:

2018 American Society of Retina Specialists Annual Meeting

 

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

Head-to-Head Comparison for nAMD Treatment

  Channels: Retina | Posted 7/20/2018

Arshad M. Khanani, MD, reviews the HAWK/HARRIER phase 3 studies on the efficacy and safety of brolucizumab (RTH258, Novartis) versus aflibercept (Eylea, Regeneron) in the treatment of neovascular age-related macular degeneration (nAMD).

aflibercept • Age-Related Macular Degeneration • ASRS Vancouver 2018 • brolucizumab (RTH258; Alcon/Novartis) • Macular Degeneration


14 / 17 Series: 2018 American Society of Retina Specialists Annual Meeting